Saluda’s Evoke SCS Set To Join Competitive US Spine-Stim Market In Late 2022
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
You may also be interested in...
News We’re Watching: Dexcom Expands In Ireland; Neurostim Updates From NANS; Novel Nanoparticles Treat Cancer In Mice; And More
Medtech Insight's News We're Watching highlights medtech industry and R&D developments that you may have missed over the last few weeks. This update covers some late-breaking results announced at the North American Neuromodulation Society (NANS) annual meeting in Las Vegas, as well as an update on Dexcom's new facility in Ireland, and a promising mouse experiment with nanoparticles that kill cancer cells.
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.